Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-23T06:13:30.469Z Has data issue: false hasContentIssue false
  • English
  • Français

Isotretinoin therapy and depression – evidence for an association

Published online by Cambridge University Press:  13 June 2014

Alan Byrne ,
Morgan Costello ,
Elaine Greene  and
Terry Zibin
Morgan Costello
Affiliation:
St Loman's Hospital, Palmerstown, Co Dublin, Ireland
Elaine Greene
Affiliation:
Eastern Health Board Mental Handicap Service, Ballyboden, Dublin 14, Ireland
Terry Zibin
Affiliation:
Alberta Hospital Ponoka, Alberta, Canada
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The object of this paper is to evaluate the evidence suggesting an association between the use of the anti-acne agent isotretinoin and the subsequent development of depression.

Method: Three case histories of individuals who had received treatment with isotretinoin and subsequently developed depression are reviewed.

Results: All three individuals were noted to have a depressive illness which was notable by the prominence of symptoms of irritability, agitation and aggression.

Conclusions: The indications from the three cases described suggest that there appears to be an association between depression and the recent use of isotretinoin. This may relate to the ability of isotretinoin to simulate hypovitaminosis A, with aggression, irritability and depression as a direct result of this effect. Young males may be particularly prone to developing this response.

Keywords

IsotretinoinDepressionAgitationAggression
Type
Brief Report
Information
Irish Journal of Psychological Medicine , Volume 15 , Issue 2 , June 1998 , pp. 58 - 60
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Ginsberg, H, Rubenstein, A, Brown, WV. Medical complications of isotretinoin. Clin Dermatol 1986; 4(1): 183–9.CrossRefGoogle ScholarPubMed
2.Bonnetblanc, JM, Hugon, AJ, Dumas, M. Intracranial hypertension with etretinate. Lancet 1983; ii: 974.Google Scholar
3.Marsden, JR. Lipid metabolism and retinoid therapy. Pharmacol Ther 1975; 40: 55–65.Google Scholar
4.Roenigk, HH Jr.Liver toxicity of retinoid therapy. J Am Acad Dermatol 1988; 19: 199–208.Google Scholar
5.McIvor, A. Fatal toxic epidermal necrolysis associated with etretinate. BMJ 1992; 304: 548.CrossRefGoogle ScholarPubMed
6.David, M, Hodak, E, Lowe, N. Adverse effects of retinoids. Medical Toxicology 1988; 3: 273–88.Google Scholar
7.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.Google Scholar
8.Scheineman, PL, Peck, GL, Rubinow, DR, DiGiovanna, JJ. Acute depression from isotretinoin. J Am Acad Derm 1990; 1112–4.Google Scholar
9.Saurat, H. Side-effects of systemic retinoids and their clinical management. J Am Acad Derm 1992; 27: S23–S28.Google Scholar
10.Mandell, HG. Fat soluble vitamins. In: Goodman, LS and Gilman, A, eds. The Pharmacological Basis of Therapeutics. New York: MacMillan, 1975: 1570–7.Google Scholar
11.Bravard, P, Krug, M, Rzeznick, JC. Isotretinoin et depression, soyons vigilantes. Nouveau Dermatologie 1993; 12: 215.Google Scholar
12.Gatti, S, Serri, F. Acute depression from isotretinoin. J Am Acad Derm 1991; 25: 132.Google Scholar
13.Peck, GL, DiGiovanna, JJ, Rubinow, DR. Acute depression from isotretinoin, reply. J Am Acad Derm 1991; 25: 132.Google Scholar
14.MacDonald Hull, S, Cunliffe, WJ, Hughes, BR. Treatment of the depressed and dysmorphophobic acne patient. Clinical and Experimental Dermatology 1991; 16: 210–11.Google Scholar
15.Goulden, V, Layton, AM, and Cunliffe, WJ. Long-term treatment with isotretinoin as a treatment for acne vulgaris. Br J Derm 1994; 131: 360–3.Google Scholar